Xeris Biopharma Holdings has seen its narrative refreshed as analysts reaffirmed a consensus fair value estimate of $11.50 per share, while making only marginal tweaks to underlying assumptions. Backed by quarterly revenues that edged past expectations and sustained revenue growth projections of about 21.8% year over year, the updated view balances optimism over market expansion with caution around competitive and macro risks. Investors can follow these evolving analyst expectations and the shifting story around Xeris Biopharma going forward.

Stay updated as the Fair Value for Xeris Biopharma Holdings shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Xeris Biopharma Holdings.

???? Bullish Takeaways

Piper Sandler, via analyst David Amsellem, lifted its Xeris Biopharma price target to $8 from $6. This signals increased confidence in the company’s medium term value even while maintaining a Neutral stance.

The firm highlights that Q3 revenue of $74.4M modestly exceeded Street expectations of $74.2M. This supports the view that Xeris is executing well on commercial rollout and sustaining growth momentum.

Analysts at Piper Sandler point to Recorlev’s traction in an expanding hypercortisolism market as a key driver that can underpin sustainable cash generation and support the valuation case over time.

???? Bearish Takeaways

Despite the higher price target, Piper Sandler keeps a Neutral rating. This underscores lingering reservations that much of the near term upside may already be reflected in the share price.

The firm also notes that Q3 EPS came in at $0.00 versus Street estimates of $0.01. This reinforces a more cautious stance around profitability, near term execution risk, and how quickly Xeris can translate revenue growth into durable earnings power.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Xeris Biopharma updated its full year 2025 earnings guidance, now projecting total revenue of $285M to $290M, indicating roughly 42% growth at the midpoint versus the prior year.

Management reiterated expectations for steady double digit top line expansion, citing continued uptake of its commercial portfolio and increasing physician awareness in key endocrine indications.

Analysts highlighted the raised 2025 outlook as a sign of growing confidence in Xeris Biopharma’s ability to scale its revenue base while navigating competitive dynamics and broader macro uncertainty.

Consensus analyst fair value estimate remains unchanged at $11.50 per share.

Discount rate has decreased marginally from 6.96% to 6.96%.

Revenue growth projection holds steady at approximately 21.8% year over year.

Net profit margin expectation is unchanged at roughly 20.2%.

Future price to earnings (P/E) ratio forecast remains stable at 29.38x.

Narratives on Simply Wall St turn raw numbers into a clear, forward looking story. They connect a company’s business reality to detailed forecasts for revenue, earnings, and margins, and then to an estimated fair value. Hosted on the Community page, Narratives are easy to use, continuously updated as news and earnings hit, and help investors compare fair value to the current share price.

Head over to the Simply Wall St Community and follow the Narrative on Xeris Biopharma Holdings to stay on top of:

How growing demand for Recorlev and Gvoke relates to revenue trends and cash generation.

Whether expansion into underserved endocrine markets influences long term profit margins.

How execution risks, competition, and reliance on a focused portfolio may affect the gap between fair value and the current price.

Read the full Xeris Biopharma Holdings Narrative here: XERS: Expanding Hypercortisolism Market Presence Will Drive Future Cash Generation.

Curious how numbers become stories that shape markets? Explore Community Narratives

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include XERS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com